SecBot SecBot
SECBOTREPLAY Home › Report › TARS

TARS · Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and raised…

Tarsus Pharmaceuticals, Inc. · 8-K filed Aug 6, 2026 at 07:23 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 6, 2026 at 07:23 ET

Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and raised full-year XDEMVY guidance to $685-705M, but EPS of -$0.43 missed consensus of -$0.20 by 119%. The company also announced a pending acquisition of Alkeus Pharmaceuticals and a $125M private placement, expanding into retina with a Phase 3 Stargardt disease program. The strong revenue beat and guidance raise are offset by the massive EPS miss and dilution from the financing, creating a mixed picture for traders.

  • Q2 2026 XDEMVY net product sales of $173.9M, up >69% YoY from $102.7M
  • Full-year 2026 XDEMVY guidance raised to $685-705M from prior $670-700M
  • GAAP EPS of -$0.43 missed consensus of -$0.20 (-119.4% surprise)
  • Net loss of $18.6M vs $20.3M in prior year; operating loss widened to $19.9M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access